Effect of Tadalafil in Chronic Obstructive Lung Disease Patients Suffering From Secondary Pulmonary Hypertension

Herlev Hospital

Status: Withdrawn

Conditions: Chronic Obstructive Lung Disease

Treatments: Drug: Tadalafil

Study type: Interventional

Funder types: Other

Identifiers

NCT00506701

25

Details and patient eligibility

About

Tadalafil may lower the pulmonary artery pressure in patients with Chronic Obstructive Lung Disease and secondary pulmonary hypertension and thereby improve patients quality of life.

Full description

Twenty outpatients with Chronic Obstructive Lung Disease (COPD) and secondary pulmonary hypertension are treated in a cross-over design with Tadalafil or placebo for 4 weeks. Primary effect parameter is 6 min. walking test.

Sex: All

Ages: 45 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Clinical diagnosis of Chronic obstructive lung disease

Exclusion Criteria

• Patients with asthma

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: Triple Blind

---

0 participants in 1 patient group

Tadalafil treatment 40 mg

Experimental group

Treatment:

Drug: Tadalafil